<?xml version="1.0" encoding="UTF-8"?>
<p id="par0115">Overall, evidence suggests that the interplay between immune system of oncologic patients receiving immunotherapy and SARS-CoV-2 infection is extremely complex. What happens when a reinforced immune system faces tumor cells and CoV infected cells at the same time? Is the immune system helpful or rather an obstacle? This population of patients deserve specific attention and need tailored recommendations in this challenging situation.</p>
